Vaxart, Inc. Announces Management Change
January 16, 2024 09:22 ET
|
Vaxart, Inc.
Chief Executive Officer Andrei Floroiu Resigns Chair Michael J. Finney, Ph.D. to Serve as Interim Chief Executive Officer SOUTH SAN FRANCISCO, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Vaxart,...
Vaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers
December 21, 2023 08:00 ET
|
Vaxart, Inc.
On track to report topline data by the end of 2024 SOUTH SAN FRANCISCO, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has completed enrollment and...
Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results
November 02, 2023 16:01 ET
|
Vaxart, Inc.
Norovirus challenge study topline results indicate the potential of Vaxart’s oral pill vaccine candidate to reduce rates of norovirus infection, norovirus acute gastroenteritis and viral shedding ...
Vaxart Doses First Subject in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers
November 02, 2023 08:00 ET
|
Vaxart, Inc.
Trial evaluating the ability of oral vaccine tablets to induce breast milk antibodies and transfer of antibodies to young infants SOUTH SAN FRANCISCO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) --...
Vaxart to Host Third Quarter 2023 Business Update and Financial Results Conference Call on November 2
October 26, 2023 08:00 ET
|
Vaxart, Inc.
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report...
Vaxart to Present at World Vaccine Congress Europe 2023 on October 18-19
October 11, 2023 08:00 ET
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James F. Cummings,...
Vaxart to Participate in Fireside Chat at 2023 Cantor Global Healthcare Conference
September 21, 2023 08:00 ET
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that senior management will participate in a fireside chat at the 2023 Cantor Global...
Vaxart Announces Topline Data from the Phase 2 Challenge Study of its Monovalent Norovirus Vaccine Candidate
September 06, 2023 16:05 ET
|
Vaxart, Inc.
Study met 5 of 6 primary endpoints Vaccine was safe and well tolerated with no vaccine-related serious adverse events (SAEs) Vaccination led to a statistically significant reduction in infection...
Vaxart Provides Business Update and Reports Second Quarter 2023 Financial Results
August 03, 2023 16:01 ET
|
Vaxart, Inc.
On track to report topline data from Phase 2 GI.1 norovirus vaccine challenge study in Q3 2023 Cash runway extended into Q3 2024 Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif.,...
Vaxart to Host Second Quarter 2023 Business Update and Financial Results Conference Call on August 3
July 27, 2023 08:00 ET
|
Vaxart, Inc.
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report...